Pharmacological management of bipolar disorder: Japanese expert consensus
Open Access
- 17 June 2020
- journal article
- research article
- Published by Wiley in Bipolar Disorders
- Vol. 22 (8) , 822-830
Abstract
Objectives The aim of this study was to develop a consensus guideline by certified experts of the Japanese Society of Clinical Neuropsychopharmacology on the psychopharmacological treatment for bipolar disorders I and II (BP‐I and BP‐II), in order to fill the gap in the literature and provide more concrete guidance for challenging and controversial real‐world situations. Methods Experts were asked to assess treatment options regarding 19 clinical situations of bipolar disorder with a nine‐point Likert scale (one = “disagree” and nine = “agree”). According to the responses from 119 experts, the options were categorized into the first‐, second‐, and third‐line treatments. Results For the treatment of BP‐I, lithium monotherapy was categorized as a first‐line treatment for manic episodes (mean ± standard deviation score, 7.0 ± 2.2), depressive episodes (7.1 ± 2.0), and the maintenance phase (7.8 ± 1.8). Combination therapy of lithium and an atypical antipsychotic was endorsed for manic episodes (7.7 ± 1.7), depressive episodes with (7.1 ± 2.0) and without mixed features (6.9 ± 2.2), and the maintenance phase (6.9 ± 2.1). Similarly, in BP‐II, lithium monotherapy was categorized as a first‐line treatment for hypomanic episodes (7.3 ± 2.2), depressive episodes (7.0 ± 2.2), and the maintenance phase (7.3 ± 2.3), while combination therapy of lithium and an atypical antipsychotic was recommended for hypomanic episodes (6.9 ± 2.4).No antipsychotic monotherapy or antidepressant treatment was categorized as a first‐line treatment for any type of episode. Conclusions These recommendations reflect the current evidence and represent the experts' consensus on using lithium for the treatment of bipolar disorder. Clinicians should consider the effectiveness and adverse effects of antipsychotic and antidepressant medications for the treatment of bipolar disorder.Keywords
Funding Information
- GlaxoSmithKline
This publication has 24 references indexed in Scilit:
- Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trialJournal of Affective Disorders, 2015
- Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysisInternational Journal of Bipolar Disorders, 2014
- The Risk of Switch to Mania in Patients With Bipolar Disorder During Treatment With an Antidepressant Alone and in Combination With a Mood StabilizerAmerican Journal of Psychiatry, 2014
- Clinical and regulatory implications of active run‐in phases in long‐term studies for bipolar disorderActa Psychiatrica Scandinavica, 2013
- Efficacy and Safety of Long-Term Fluoxetine Versus Lithium Monotherapy of Bipolar II Disorder: A Randomized, Double-Blind, Placebo-Substitution StudyAmerican Journal of Psychiatry, 2010
- The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depressionThe World Journal of Biological Psychiatry, 2010
- Lithium: Updated Human Knowledge Using an Evidence-Based ApproachCNS Drugs, 2009
- The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute ManiaThe World Journal of Biological Psychiatry, 2009
- A Review of Sensitivity and Tolerability of Antipsychotics in Patients With Bipolar Disorder or SchizophreniaThe Journal of Clinical Psychiatry, 2008
- Exclusion Criteria Used in Antidepressant Efficacy TrialsJournal of Nervous & Mental Disease, 2004